Previous 10 | Next 10 |
Akari Therapeutics ([[AKTX]] -4.6%) completes a scientific advice meeting with the European Medicines Agency ((EMA)) prior to initiation of a Phase 3 study of nomacopan for the treatment of bullous pemphigoid ((BP)), a rare skin disorder characterized by large fluid-filled blisters on areas o...
The EMA and the FDA have both agreed to a Phase III randomized placebo-controlled study with nomacopan in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of disease remission on minimal oral corticosteroids (OCS) Nomacopan has been granted orphan dr...
NEW YORK and LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicat...
NEW YORK and LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicat...
Akari Therapeutics (NASDAQ: AKTX ) : Q2 GAAP EPS of $0.00. Cash of approximately $12.7M. Press Release More news on: Akari Therapeutics, Plc, Earnings news and commentary, Healthcare stocks news, ,
International clinical development program of nomacopan for the potential treatment of COVID-19 pneumonia announced Pivotal Phase III study in patients with bullous pemphigoid (BP) expected to start H1 2021 following recent successful end-of-Phase II meeting with FDA Enrollment in...
Akari Therapeutics ( AKTX +6.5% ) intends to develop nomacopan as a potential treatment for COVID-19 pneumonia through integrated clinical trial programs in U.S., U.K. and Brazil. More news on: Akari Therapeutics, Plc, Healthcare stocks news, Read more ...
Aimmune Therapeutics (NASDAQ: AIMT ) +171% on being acquired by Nestle. More news on: Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., Genworth Financial, Inc., , , Read more ...
Clinical studies both underway and planned for patients with COVID-19 pneumonia in the U.S., U.K., and Brazil Proposed multi-center U.S. randomized clinical program in regulatory submission following the treatment of patients via expanded access programs In Brazil, patient rec...
Akari Therapeutics (NASDAQ: AKTX ) announces a successful End of Phase 2 (EOP2) meeting with the FDA regarding its proposed Phase III program for the treatment of bullous pemphigoid (BP), a rare skin-blistering disorder. More news on: Akari Therapeutics, Plc, Healthcare stock...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...